



**/ immatics biotechnologies adds to management team /**  
Directors from BrainLAB and Intercell switch to Tübingen biotech company

**Tübingen, January 26, 2005.** Tübingen-based immatics biotechnologies GmbH, specialists in immunotherapeutics against cancer, has expanded its management team: The company's new Chief Medical Officer (CMO) is Jürgen Frisch, previously a board member at Intercell AG in Vienna, and the new Finance Director / CFO is Jörg Scheidle, latterly CFO North America at medical equipment suppliers BrainLAB AG. They add to the existing team around Niels Emmerich (COO) and Harpreet Singh (CSO).

Jürgen Frisch (50), as Chief Medical Officer, latterly directed development at Intercell AG in Vienna, bringing their first vaccine candidates to the phase II stage of clinical development. Prior to that, Frisch, who holds a doctorate in medicine, worked as Medical Director and General Manager of the Genetics Institute GmbH in Munich and as Head of Clinical Studies at the German subsidiary of Hoechst Marion Roussel in Frankfurt, where he was responsible for all studies led from Europe.

Jörg Scheidle (33), as CFO, was latterly responsible for the development of BrainLAB AG's North American business. Prior to that he had responsibility for building up the accounting, financial control and investor relations departments, as well as preparing the renowned medical equipment supplier's stock market flotation. A business graduate and MBA, Scheidle started out in 1997 as Executive Assistant to BrainLAB AG's founder and CEO.

"The two newcomers complete a highly professional management team", says Thomas Widman, co-founder of the Swiss Actelion AG and nowadays Chairman of immatics' supervisory board. "The management of immatics thus has both investor relations experience and over two decades of experience in both clinical development and the pharmaceutical approvals process. This is an almost unique line-up for such a young biotech company."

### **About immatics**

Founded in the year 2000 as a spin-off from the University of Tübingen, immatics biotechnologies GmbH identifies and validates new immunotherapeutic substances for fighting cancer and will this year bring a first product candidate against renal cell carcinoma into clinical development. Renal cell carcinoma is one of the ten most common forms of cancer and is regarded as resistant to normal types of chemotherapy, so the medical need in this area is therefore particularly high. With the help of the company's own technology platform, immatics has also identified and patented numerous further antigens (so-called TUMAPs or tumour-associated peptides) for other cancer indications.

At the start of 2004, a consortium led by Wellington Partners and 3i invested €8.3m in immatics – the largest example of first-round funding for a German biotech company since 2002. Members of the supervisory board include the founder of Actelion, Thomas Widmann (Chairman), GPC Biotech director Sebastian Meier-Ewert and Ulrich Granzer (formerly Global Head of Regulatory Affairs at Bayer, BASF Knoll and Glaxo Wellcome).

**Reprint free of charge – Please provide specimen copy**

### **Further information**

immatics biotechnologies GmbH  
Dr. Niels Emmerich  
Managing Director / COO  
Paul-Ehrlich-Str. 15  
D-72076 Tübingen  
Tel: +49 (0) 7071 565 125-0  
Fax: +49 (0) 7071 565 125-99  
Mail: emmerich@immatics.com